TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Cerebrospinal fluid (CSF) biomarkers of risk for Alzheimer's disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Structural MRI hippocampal volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: MRI-ASL vasoreactivity response to CO2 challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of Acute Heart Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Weight-bearing Ratio During Five Times Sit-to-Stand Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of severe hypoglycemia
Endpoint domain: Adverse events/effects
Primary endpoint: change in FLACC score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Repeat Paracentesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Composite primary endpoint of stroke, systemic embolism, or cardiovascular or unexplained death
Endpoint domain: Mortality/survival
Primary endpoint: Plasma concentrations of ritonavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentrations of Darunavir (DRV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Production and fractional catabolism of apolipoprotein A-I and A-II
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma levels of apolipoprotein A-I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma levels of apolipoprotein A-II
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma levels of high-density lipoprotein cholesterol (HDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Severe peripheral sensory neurotoxicity rates
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of urine samples negative for cocaine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of urine samples negative for opiates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of urine samples negative for cocaine and opiates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Progression-free Survival at 1 Year
Endpoint domain: Mortality/survival
Primary endpoint: long term clinical outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: childhood developmental outcomes
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: family impact
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Platelet engraftment rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean Change in Synovitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: NRS for pruritus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of antiemetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change of LDL plasma cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage change of total plasma cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of pushes reported
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal Death or Sepsis Within 6 Weeks Post-delivery
Endpoint domain: Mortality/survival
Primary endpoint: Intrapartum/Neonatal Death or Sepsis Within 4 Weeks Post-delivery
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants With Major Cytogenetic Response (MCyR) at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Modification of respiratory kinematic
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Skin-to-delivery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of avoidable task interruptions
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: sources and frequencies of task interruptions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Delta-HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Mayo score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interleukin 10 plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Achievement of Hemostasis at the Target Bleeding Site
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in chemotherapy-related fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Incidence of Grade 3/4 neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Overall objective response rate (RR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dental color measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 24-hour Average Pain Item Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wexner overall score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of recordings fulfilling requirements for observation and classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ease of use of the In-Motion App (SUS score)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Correlation between computer-based software estimates and standard videos
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary graft dysfunction (PGD) prevention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in QT interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Women Who Received Systemic Narcotic Analgesics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Clinical Global Impression of Severity (CGI-S) Status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in Clinical Global Impression - Improvement (CGI-I)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in Peak FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Confirmed Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Improvement in Acne IGA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number and severity of toxicity incidents
Endpoint domain: Adverse events/effects
Primary endpoint: Likelihood of Biochemical Recurrence (BCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference of recurrence rate before and after intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: change of HBsAb titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Biochemical Progression-Free Survival (bPFS) Proportion
Endpoint domain: Mortality/survival
Primary endpoint: Changes in the glucagon-incretin axis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in the gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of Systemic Embolisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total time for TRV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CTCAE drug related grade 4 toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: clinical and parasitological treatment failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Count erythrocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Fibromyalgia symptoms evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastrointestinal symptoms evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Functional evolution
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of Overall Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Periodontal bone regeneration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Respiratory Disease Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: angle of muscle reaction (R1 angle)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and feasibility of treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Smoking Cessation at 7 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Continuous Smoking Abstinence at 6 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: loss of water throughout epidermis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: throatiness of epidermis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Proportion of sick children completing the referral process
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants With One or More Adverse Events Related to Study Drug
Endpoint domain: Adverse events/effects
Primary endpoint: Remission rate (cytologic, molecular)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Jebsen Taylor Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: death or myocardial infarction at 3-year after stent implantation
Endpoint domain: Mortality/survival
Primary endpoint: Coefficient of variation for area of increased illumination under the RPE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Virtual Multiple Errands Test performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Fascial defect area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroprotection (Seroconversion for Pertussis)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: The pain of breast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The days of pain
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: The target lump
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to Resolution of cough
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative Change in the Index of Microcirculatory Resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ABPM systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall Satisfaction With Study Treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 60 second sit to stand test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventricular activation patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hydroxyurea adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area under the plasma concentration versus time curve (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Subjects Alive and Discharged From the Hospital
Endpoint domain: Mortality/survival
Primary endpoint: Minimum effective optimum dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvement in gastrointestinal complaints
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mini-screw implant success or failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Changes in pain-related disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Average of Individual readiness assessment test (IRAT) grades
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Anti-hepatitis A (HAV) Antibody Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-hepatitis B (HBs) Antibody Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean numeric pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delivery type
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Time to potential occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in the score of the upper-extremity section of Fugl-Meyer assessment scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the score of Modified Ashworth Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of penetrative unprotected sexual intercourse occasions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The proportion of sex episodes involving alcohol or other drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The proportion of penetrative unprotected sex occasions (of all sex occasions)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immuno-virologic criterion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of patients disease-free
Endpoint domain: Mortality/survival
Primary endpoint: Number of endotracheal intubations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Lower Urinary Tract Symptoms (LUTS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes in Liver Fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: PGE Concentration in the Alveolar Portion of BAL Fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Feeding disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of hypoglycaemias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: drug discontinuation rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of complete abortions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change From Baseline to Week 12 in Severity of the Most Bothersome Symptom of Vaginal Dryness Associated With Sexual Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline to Week 12 in Severity of the Most Bothersome Symptom of Vaginal Pain Associated With Sexual Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline to Week 12 in Vaginal pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete healing of the lesion(s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wheal size area of the immediate phase reaction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects experiencing a Serious Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Inflammatory markers (CRP, IL-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fractional flow reserve (FFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in pain Numerical Rating Scale (NRS) from pre-treatment to post treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expelled Perspiration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetics of teduglutide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With EEGs to Measure Changes in Wave Oscillations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Motor Symptom Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of pneumoperiteum laparoscopic workspace
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: score SRS (Surgical Rating Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: percent change in acne lesion counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: 2-year Relapse Free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: atherogenic lipid oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Endothelium-dependent flow-mediated dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in Numeric Rating Scale (NRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Modified Ashowreth Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Gross Motor Function Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Cerebral Palsy Quality of Life Questionnaire (Emotional well-being dimension)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cumulative incidence of locally recurrent rectal cancer
Endpoint domain: Mortality/survival
Primary endpoint: Overall survival of patients with locally recurrent rectal cancer
Endpoint domain: Mortality/survival
Primary endpoint: adhesion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: iPFS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Von Willebrand factor (VWF) multimer defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: NK cell numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Actigraphy Total Sleep Time (TST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Response (no Emesis, Significant Nausea or Rescue Medication)
Endpoint domain: Adverse events/effects
Primary endpoint: Late Adverse Event Incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Pain intensity measured by verbal numeric scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of complete enteroscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Lesion discovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time to Treatment (TTT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects developing major cutaneous reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Amplitude of post-occlusive hyperemia and thermal hyperemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: adverse events reporting
Endpoint domain: Adverse events/effects
Primary endpoint: clinical safety laboratory tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Lens Opacification Event Development or Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Changes to the gut microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Occurrence of Palms with HFS severity grade 2 or 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound healing/scarring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: remission rate of NAFLD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: histological remission of NASH without worsening of fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uptake and retention of 3'-deoxy-3'-[18F] fluorothymidine (FLT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in thymidine kinase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in thymidylate synthase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total GLP-1 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Intact GIP concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes